Kinnate Biopharma Alpha and Beta Analysis
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kinnate Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kinnate Biopharma over a specified time horizon. Remember, high Kinnate Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kinnate Biopharma's market risk premium analysis include:
Beta 2.2 | Alpha (0.09) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Kinnate |
Kinnate Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kinnate Biopharma market risk premium is the additional return an investor will receive from holding Kinnate Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kinnate Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kinnate Biopharma's performance over market.| α | -0.09 | β | 2.20 |
Kinnate Biopharma Fundamentals Vs Peers
Comparing Kinnate Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kinnate Biopharma's direct or indirect competition across all of the common fundamentals between Kinnate Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kinnate Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kinnate Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Kinnate Biopharma to competition |
| Fundamentals | Kinnate Biopharma | Peer Average |
| Return On Equity | -0.56 | -0.31 |
| Return On Asset | -0.34 | -0.14 |
| Current Valuation | (25.71 M) | 16.62 B |
| Shares Outstanding | 47.17 M | 571.82 M |
| Shares Owned By Insiders | 0.15 % | 10.09 % |
| Shares Owned By Institutions | 82.58 % | 39.21 % |
| Number Of Shares Shorted | 465.63 K | 4.71 M |
Kinnate Biopharma Opportunities
Kinnate Biopharma Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences | 06/01/2023 |
About Kinnate Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kinnate or other delisted stocks. Alpha measures the amount that position in Kinnate Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Kinnate Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Kinnate Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kinnate Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kinnate Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kinnate Biopharma. Please utilize our Beneish M Score to check the likelihood of Kinnate Biopharma's management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Kinnate Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |